Heart Disease Trial, Recruiting (NCT06809686)

Heart Disease Trial, Recruiting NCT06809686 Sponsor: Richmond Research Institute Condition: Heart Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06809686 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Heart Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are between 45 and 80 years old (inclusive) at the time of signing the consent form
People who have been diagnosed with heart failure
People who are willing and able to give their informed consent to take part in the study

Who may not be able to join:

People who have tested positive for HIV-1 or HIV-2
People who have tested positive for Hepatitis B or Hepatitis C
People who, in the investigator's judgement, may not be able to understand or cooperate with the study requirements due to mental capacity, language barriers, or unwillingness to follow the study procedures
People who have a condition that the investigator considers would put them at undue risk by participating in the trial
People whose test results are not consistent with a specific type of heart failure (known as heart failure with mildly reduced or preserved ejection fraction), as determined by the investigator (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Principal Investigator, Richmond Pharmacology

Phone: +44 (0) 207 042 5800

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06809686

Sponsor: Richmond Research Institute

Phase: Not Applicable

Status: Recruiting

Condition: Heart Disease

Trial contact: +44 (0) 207 042 5800

More information: https://clinicaltrials.gov/study/NCT06809686

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are between 45 and 80 years old (inclusive) at the time of signing the consent form
People who have been diagnosed with heart failure
People who are willing and able to give their informed consent to take part in the study

Who may not be able to join:

People who have tested positive for HIV-1 or HIV-2
People who have tested positive for Hepatitis B or Hepatitis C
People who, in the investigator's judgement, may not be able to understand or cooperate with the study requirements due to mental capacity, language barriers, or unwillingness to follow the study procedures
People who have a condition that the investigator considers would put them at undue risk by participating in the trial
People whose test results are not consistent with a specific type of heart failure (known as heart failure with mildly reduced or preserved ejection fraction), as determined by the investigator (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Richmond Research Institute

Registry

ClinicalTrials.gov

Start date

5 February 2025

Est. completion

21 January 2027

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

To generate high quality ECG data to establish an ECG library for the development of an ECG tool to monitor disease progression.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov